Interleukin-1 beta; Interleukin-6; Toll-like receptor 4; Myeloid differentiation primary response protein MyD88; Nuclear factor kappa-light-chain-enhancer of activated B cells (IL-1β; IL-6; TLR4; MyD88; NF-κB)

This grouping includes IL-1β and IL-6, which are key pro-inflammatory cytokines; TLR4, a cell-surface pattern recognition receptor central to sensing microbial and endogenous danger signals; MyD88, an adaptor protein essential for activating downstream signaling from TLR4 and interleukin receptors; and NF-κB, a transcription factor that orchestrates expression of immune and inflammatory genes. The combined TLR4/MyD88/NF-κB pathway is pivotal in innate immunity and is activated following recognition of pathogens or tissue damage, leading to cytokine production (including IL-1β and IL-6) and immune cell recruitment. Overactivity of this pathway contributes to inflammatory, autoimmune, cardiovascular, and metabolic diseases, and all components have been individually and collectively targeted for drug development, though such interventions may pose notable safety risks, especially concerning immune suppression[2][3][5][6]. This entry is not a singular canonical molecular target but a composite of several key molecules and cascade components. For structured information, each protein or pathway node should be treated individually.

Other names

Interleukin-1 beta (IL-1β), IL1BInterleukin-6 (IL-6), IL6Toll-like receptor 4 (TLR4)Myeloid differentiation primary response protein MyD88 (MyD88)Nuclear factor kappa B (NF-κB)

Neutralization or receptor antagonism to inhibit cytokine activity and downstream inflammation. Blockade reduces activation of downstream MyD88/NF-κB signaling, dampening the inflammatory response. Prevent activation of transcription factor, reducing expression of pro-inflammatory genes.